Sanofi's Net Sales Breakdown by Product Family and Geographical Distribution

The UK's MHRA has approved Teplizumab to delay the progression of type 1 diabetes. Sanofi's net sales are primarily driven by pharmaceutical products (79.8%), with a significant portion coming from specialty medicine (63.2%) and general medicine (36.8%). The group also generates revenue from human vaccines (20.2%). Sanofi has 52 production sites worldwide and is distributed geographically across France, Europe, the US, China, and other regions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) by an average of three years in adults and children aged 8 years and older with Stage 2 T1D. This marks the UK’s first-ever approved immunotherapy for type 1 diabetes [1].

Teplizumab is administered via intravenous infusion once daily for 14 days and is intended for people with Stage 2 T1D, an earlier stage of the disease where individuals are at high risk of progressing to Stage 3. The MHRA approved the drug through the International Recognition Procedure (IRP), allowing it to consider the expertise and decision-making of trusted regulatory partners for the benefit of UK patients [1].

Sanofi SA, which is a significant player in the pharmaceutical industry, is set to benefit from this approval. Sanofi's net sales are primarily driven by pharmaceutical products (79.8%), with a substantial portion coming from specialty medicine (63.2%) and general medicine (36.8%). The company also generates revenue from human vaccines (20.2%) [2]. Sanofi has 52 production sites worldwide and is distributed geographically across France, Europe, the US, China, and other regions [2].

In addition to the MHRA approval, Sanofi has initiated a clinical study in Japan to evaluate the efficacy and safety of teplizumab in Japanese pediatric and adult participants aged 8 to 34 years with Stage 2 Type 1 Diabetes. This study aims to extend the investigation to a Japanese cohort, potentially broadening the therapeutic application of Teplizumab [2].

The global vaccines market is also experiencing significant growth, with an increase from USD 76.05 billion in 2024 to USD 118.85 billion by 2030 at a CAGR of 7.72%. Technological advancements such as messenger RNA platforms and synthetic biology are revolutionizing vaccine development, while blockchain and IoT are improving supply chain efficiency [3].

The approval of teplizumab and the ongoing clinical study in Japan could positively influence Sanofi’s stock performance. Successful results may enhance the market potential of Teplizumab in new regions, potentially driving growth for the company. Investors should watch for competitive responses, as advancements in diabetes treatment are highly impactful in the pharmaceutical industry.

References:
[1] https://www.gov.uk/government/news/mhra-approves-teplizumab-to-delay-progression-of-type-1-diabetes
[2] https://www.theglobeandmail.com/investing/markets/stocks/SNY/pressreleases/34006193/sanofis-teplizumab-study-in-japan-a-potential-game-changer-for-type-1-diabetes/
[3] https://www.globenewswire.com/news-release/2025/08/14/3133388/28124/en/Assessment-of-the-118-Billion-Vaccines-Market-2030-Featuring-Strategic-Analysis-of-30-Industry-Players.html